Skip to Main Content
Skip Nav Destination

AstraZeneca Joins Radiopharmaceutical Rush

March 26, 2024

Abstract: AstraZeneca announced plans to buy Fusion Pharmaceuticals for up to $2.4 billion, a deal that reflects a growing interest in targeted radiopharmaceuticals for cancer treatment. The move, which follows recent acquisitions by Bristol-Myers Squibb and Eli Lilly, signals a collective bet on the potential of radiolabeled therapies, with a focus on new types of radioisotope designs and tumor-targeting mechanisms.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal